EGFR/CD47 BsAb / LightChain Bioscience - LARVOL DELTA

Bispecific antibodies targeting EGFR and HER2 for effective killing of solid tumor cells via a safe CD47-SIRPA modulation (AACR 2026) - "INTRODUCTION: The CD47-SIRPα axis is a crucial immune checkpoint, allowing tumor cells to evade immune destruction. The "unbalanced affinities" design of TAA/CD47 bispecific antibodies effectively addresses the safety and pharmacokinetic liabilities observed with monospecific CD47 antibodies. Importantly, our clinical experience with NI-1801 (MSLN×CD47) validates both the safety and the potential clinical benefit of this tumor-restricted CD47-blocking strategy (1). Together, these findings support TAA/CD47 bsAbs as a valuable addition to the anti-cancer armamentarium, with the EGFR/CD47 and HER2/CD47 bsAbs described here representing promising development candidates."

Bispecific • Tumor cell • Oncology • Ovarian Cancer • Solid Tumor • CD47 • EGFR • HER-2 • MSLN • SIRPA